Hims & Hers Health (NYSE:HIMS) Shares Down 5% Following Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price traded down 5% during trading on Tuesday after Truist Financial lowered their price target on the stock from $48.00 to $37.00. Truist Financial currently has a hold rating on the stock. Hims & Hers Health traded as low as $43.21 and last traded at $42.84. 6,014,452 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 33,741,582 shares. The stock had previously closed at $45.10.

Other equities analysts have also issued reports about the stock. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a research report on Monday, June 23rd. Bank of America raised their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research report on Tuesday, April 29th. Piper Sandler reaffirmed a “neutral” rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Morgan Stanley reaffirmed an “equal weight” rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Two equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and an average price target of $38.92.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 2,572 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $51.64, for a total value of $132,818.08. Following the completion of the sale, the insider directly owned 153,021 shares in the company, valued at $7,902,004.44. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Chi sold 2,100 shares of Hims & Hers Health stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total transaction of $120,792.00. Following the sale, the insider owned 278,654 shares of the company’s stock, valued at $16,028,178.08. The trade was a 0.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,273,034 shares of company stock valued at $66,425,573 in the last ninety days. 17.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth $26,000. Quaker Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth $29,000. Bessemer Group Inc. lifted its stake in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the first quarter worth $30,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its stake in shares of Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after buying an additional 600 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 6.5%

The company’s 50 day moving average price is $52.47 and its 200 day moving average price is $45.75. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The firm has a market capitalization of $9.53 billion, a price-to-earnings ratio of 52.72, a P/E/G ratio of 2.86 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same quarter in the previous year, the firm posted $0.06 earnings per share. The company’s quarterly revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.